Drug intelligence / Profile preview

PMB-702

Development stage: Unknown
Lead developer: PiMedBio
Modality: Small Molecules

Overview

PMB-702 is a small molecule drug candidate developed by Pimedbio for the treatment of inflammatory bowel diseases (IBD) and other digestive system disorders. It is described as a novel IBD therapeutic and is currently in the discovery phase of development. The drug appears to be part of Pimedbio's platform focused on bispecific small molecules and inhibitor-drug conjugates, suggesting it may have a dual-targeting mechanism or innovative molecular design. While specific targets are not disclosed for this compound in public sources, related research from Pimedbio indicates an interest in dual inhibition strategies such as FGFR/HDAC inhibitors for overcoming resistance mechanisms in disease models[1][5][9].

Other names: IBD Therapeutic Agents (Pimedbio)IBD therapeutic agent (Pimedbio)

Beyond the preview

Go deeper on PMB-702.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMB-702.

Explore the full profile